Intellect Neurosciences, Inc. in Dispute With Pharmaceutical Licensee Over $2 Million Milestone Payment

NEW YORK, July 11, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer’s and other neurological diseases, announced today an update to previously disclosed patent news.

MORE ON THIS TOPIC